Enhancing the CDC Autocidal Gravid Ovitrap to control dengue vectors.
This grant opportunity is focused on developing improvements to the Autocidal Gravid Ovitrap (AGO) used for controlling Aedes aegypti mosquitoes, which spread dengue and other arboviruses. It seeks Phase I Small Business Innovation Research (SBIR) proposals, with a funding limit of up to $243,500 for a 6-month duration, and a potential Phase II funding of up to $2,045,816 for up to 2 years. Pr…
Source
Dates
Program & Phase
Keywords
Supporting Links
Documents
Similar Opportunities
-
Deployed Warfighter Protection FY27
ACC-APG-Detrick
-
HIV Prevention and Alcohol (R34 Clinical Trials Optional)
National Institutes of Health ▸ National Institute on Alcohol Abuse and Alcoholism
-
Research and Development for Biological Control of Arundo Donax
Engineer Research and Development Center
-
Leveraging Network Infrastructure to Conduct Innovative Research for Women, Children, Pregnant and Lactating Women, and Persons with Disabilities (UG3/UH3 - Clinical Trial Optional)
National Institutes of Health
-
DoW Tick-Borne Disease Therapeutic/Diagnostic Research Award
Dept. of the Army -- USAMRAA
Find tens of thousands more opportunities — free
Scout accounts are free. Sign up to browse the full funding database, unlock the solicitation links and documents for this opportunity, and see how well each one fits your organization.
-
Tens of thousands of funding opportunities
Search and filter every grant and solicitation in Scout — all free, no credit card required.
-
Instant Fit Analysis
Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
-
Source links & full documents
Jump straight to the solicitation and download every attachment.
-
Save opportunities & track deadlines
Keep the opportunities that fit in one place and stay ahead of every due date.
Already have an account? Sign In
Trusted by 500+ Happy Customers